Prolonged cellular midostaurin retention suggests potential alternative dosing strategies for FLT3-ITD-positive leukemias

Leukemia. 2016 Oct;30(10):2090-2093. doi: 10.1038/leu.2016.127. Epub 2016 May 3.

Authors

D B Lipka¹, M-C Wagner¹, M Dziadosz², T Fischer¹

Affiliations

¹ Department of Hematology and Oncology, Medical Center, Otto-von-Guericke-University, Magdeburg, Germany.
² Institute of Forensic Medicine, Medical Center, Otto-von-Guericke-University, Magdeburg, Germany.

No abstract available

Publication types

Letter

MeSH terms

Animals
Antineoplastic Agents / therapeutic use*
Culture Media
Dose-Response Relationship, Drug
Humans
Leukemia, Myeloid, Acute / drug therapy*
Mice
Staurosporine / analogs & derivatives*
Staurosporine / metabolism
fms-Like Tyrosine Kinase 3 / genetics*

Substances

Antineoplastic Agents
Culture Media
FLT3 protein, human
fms-Like Tyrosine Kinase 3
Staurosporine
midostaurin